Elevated lipoprotein(a) - A genetic risk factor for premature vascular disease in people with and without standard risk factors: A review

Disease-a-Month

Volumn 52, Issue 1, 2006, Pages 5-50

  Enas, Enas A ^a   Chacko, Vinod ^a   Senthilkumar, A ^a   Puthumana, Neal ^a   Mohan, V ^b  

^a CADI Research Foundation   (United States)

^b MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGE DISTRIBUTION; ATHEROSCLEROSIS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DYSLIPIDEMIA; ETHNIC DIFFERENCE; GENETIC RISK; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LABORATORY DIAGNOSIS; LIPOPROTEIN BLOOD LEVEL; RESTENOSIS; REVIEW; SEX RATIO; STROKE; THROMBOSIS;

EID: 33645034893     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2006.01.002     Document Type: Article

References (336)

1. K. Berg A new serum type system in man the LP system Acta Pathol Microbiol Scand 59 1963 369 382
2. G. Luc, J.M. Bard, D. Arveiler Lipoprotein(a) as a predictor of coronary heart disease the PRIME Study Atherosclerosis 163 2 2002 377 384
3. N. Rifai, J. Ma, F.M. Sacks Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men The Physicians' Health Study Clin Chem 50 2004 1364 1371
4. T.T. Nguyen, R.D. Ellefson, D.O. Hodge Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women Circulation 96 5 1997 1390 1397
5. A.G. Bostom, L.A. Cupples, J.L. Jenner Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study JAMA 276 7 1996 544 548
6. G.H. Dahlen, S.R. Srinivasan, H. Stenlund The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States J Intern Med 244 5 1998 417 424
7. G. Assmann, H. Schulte, A. von Eckardstein Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men Am J Cardiol 77 14 1996 1179 1184
8. J.K. Gambhir, H. Kaur, D.S. Gambhir Lipoprotein(a) as an independent risk factor for coronary artery disease in patients below 40 years of age Indian Heart J 52 4 2000 411 415
9. V. Mohan, R. Deepa, S.P. Haranath Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India Diabetes Care 21 11 1998 1819 1823
10. P.N. Hopkins, L.L. Wu, S.C. Hunt Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease Arterioscler Thromb Vasc Biol 17 11 1997 2783 2792
11. A. von Eckardstein, H. Schulte, P. Cullen Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk J Am Coll Cardiol 37 2 2001 434 439
12. E.A. Enas Lipoprotein(a)is an important genetic risk for coronary artery disease in Asian Indians Am J Cardiol 88 2 2001 201 202
13. E.A. Enas, J. Mehta Malignant coronary artery disease in young Asian Indians Thoughts on pathogenesis, prevention, and treatment Clin Cardiol 18 1995 131 135
14. S. Anand, E.A. Enas, J. Pogue Elevated lipoprotein(a) levels in South Asians in North America Metabolism 47 2 1998 182 184
15. E.A. Enas, J. Dhawan, S. Petkar Coronary artery disease in Asian Indians lessons learned so far and the role of Lp(a) Indian Heart J 49 1997 25 34
16. R.C. Hoogeveen, J.K. Gambhir, D.S. Gambhir Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts J Lipid Res 42 4 2001 631 638
17. R.M. Lawn Lipoprotein(a) in heart disease Sci Am 266 6 1992 54 60
18. M.L. Koschinsky, S.M. Marcovina Structure-function relationships in apolipoprotein(a) insights into lipoprotein(a) assembly and pathogenicity Curr Opin Lipidol 15 2 2004 167 174
19. M.B. Boffa, S.M. Marcovina, M.L. Koschinsky Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis mechanistic insights from animal models Clin Biochem 37 5 2004 333 343
20. M.L. Koschinsky Lipoprotein(a) and the link between atherosclerosis and thrombosis Can J Cardiol 20 suppl B 2004 37B 43B
21. K.A. Hajjar, R. Nachman The role of lipoprotein(a) in atherogenesis and thrombosis Annu Rev Med 47 1996 423 442
22. M. Naruszewicz, E. Selinger, J. Davignon Oxidative modification of lipoprotein(a) and the effect of beta-carotene Metabolism 41 11 1992 1215 1224
23. L.B. Nielsen Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein insight from in vivo studies of arterial wall influx, degradation and efflux Atherosclerosis 143 2 1999 229 243
24. M. Poon, X. Zhang, K.G. Dunsky Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells Circulation 96 8 1997 2514 2519
25. D.J. Grainger, H.L. Kirschenlohr, J.C. Metcalfe Proliferation of human smooth muscle cells promoted by lipoprotein(a) Science 260 5114 1993 1655 1658
26. T. Syrovets, J. Thillet, M.J. Chapman Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes Blood 90 5 1997 2027 2036
27. S. Takami, S. Yamashita, S. Kihara Lipoprotein(a) enhances the expression of intracellular adhesion molecule-1 in cultured human umbilical vein endothelial cells Circulation 97 1998 721 728
28. K.E. Sorensen, D.S. Celermajer, D. Georgakopoulos Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level J Clin Invest 93 1 1994 50 55
29. S.P. Zha, D.Y. Xu Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells Clin Chim Acta 296 1-2 2000 121 133
30. D.J. Grainger, P.R. Kemp, A.C. Liu Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice Nature 370 6489 1994 460 462
31. E. Lutgens, M. Gijbels, M. Smook Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression Arterioscler Thromb Vasc Biol 22 6 2002 975 982
32. A. Deb, N. Caplice Lipoprotein(a) new insight into mechanisms of atherogenesis and thrombosis Clin Cardiol 27 2004 258 264
33. J.D. Morrisett The role of lipoprotein[a] in atherosclerosis Curr Atheroscler Rep 2 3 2000 243 250
34. W. Sangrar, L. Bajzar, M.E. Nesheim Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation Biochemistry 34 15 1995 5151 5157
35. T.M. Palabrica, A.C. Liu, M.J. Aronovitz Antifibrinolytic activity of apolipoprotein(a) in vivo human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis Nat Med 1 3 1995 256 259
36. J. Loscalzo, M. Weinfeld, G.M. Fless Lipoprotein(a), fibrin binding, and plasminogen activation Arteriosclerosis 10 2 1990 240 245
37. O.R. Etingin, D.P. Hajjar, K.A. Hajjar Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis J Biol Chem 266 4 1991 2459 2465
38. S.M. Marcovina, M.L. Koschinsky Evaluation of lipoprotein(a) as a prothrombotic factor progress from bench to bedside Curr Opin Lipidol 14 4 2003 361 366
39. H. Sun, H. Unoki, X. Wang Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a) J Biol Chem 277 49 2002 47486 47492
40. J. Fan, H. Shimoyamada, H. Sun Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet Arterioscler Thromb Vasc Biol 21 1 2001 88 94
41. J.K. Williams, D.A. Bellinger, T.C. Nichols Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a) Arterioscler Thromb 13 4 1993 548 554
42. U. Beisiegel, A. Niendorf, K. Wolf Lipoprotein(a) in the arterial wall Eur Heart J 11 suppl E 1990 174 183
43. T. Reblin, N. Meyer, C. Labeur Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques Atherosclerosis 113 2 1995 179 188
44. C.R. Rodriguez, L.J. Seman, J.M. Ordovas Lipoprotein(a) and coronary heart disease Chem Phys Lipids 67-68 1994 389 398
45. V. Schachinger, M. Halle, J. Minners Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation J Am Coll Cardiol 30 4 1997 927 934
46. H.W. Wilmink, M.J. de Kleijn, M.L. Bots Lipoprotein(a) is associated with endothelial function in healthy postmenopausal women Atherosclerosis 153 1 2000 249 254
47. H.D. Wu, L. Berglund, C. Dimayuga High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort J Am Coll Cardiol 43 10 2004 1828 1833
48. P.J. Schreiner, J.D. Morrisett, A.R. Sharrett Lipoprotein[a] as a risk factor for preclinical atherosclerosis Arterioscler Thromb 13 6 1993 826 833
49. K. Velmurugan, R. Deepa, R. Ravikumar Relationship of lipoprotein(a) with intimal medial thickness of the carotid artery in Type 2 diabetic patients in south India Diabet Med 20 6 2003 455 461
50. P.J. Schreiner, G. Heiss, H.A. Tyroler Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol 16 3 1996 471 478
51. S.K. Ryu, B.K. Hong, H.M. Kwon Age-related contribution of Lp(a) with coronary artery calcification in patients with acute coronary syndrome a potential role of metabolic disorder in calcified plaque Yonsei Med J 44 3 2003 445 453
52. H.R. Superko, H.S. Hecht Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification Am J Cardiol 88 3 2001 260 264
53. M. Peltier, M.C. Iannetta Peltier, M.E. Sarano Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis Chest 121 5 2002 1589 1594
54. W. Terres, E. Tatsis, B. Pfalzer Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) Circulation 91 4 1995 948 950
55. G. Dangas, J.A. Ambrose, D.J. D'Agate Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease Am J Cardiol 83 4 1999 583 585 A7
56. Y. Matsumoto, H. Daida, Y. Watanabe High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease J Atheroscler Thromb 5 2 1998 47 53
57. A. Tamura, T. Watanabe, Y. Mikuriya Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction Br Heart J 74 4 1995 365 369
58. J.D. Zampoulakis, A.A. Kyriakousi, K.A. Poralis Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes Clin Cardiol 23 12 2000 895 900
59. X.L. Wang, G. Cranney, D.E. Wilcken Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients Aust NZ J Med 30 3 2000 333 338
60. X.L. Wang, C. Tam, R. Mc Credie Determinants of severity of coronary artery disease in Australian men and women Circulation 89 1994 1974 1981
61. C. Gazzaruso, D. Geroldi, A. Garzaniti Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity Int J Cardiol 64 3 1998 277 284
62. G. Dangas, R. Mehran, P.C. Harpel Lipoprotein(a) and inflammation in human coronary atheroma association with the severity of clinical presentation J Am Coll Cardiol 32 7 1998 2035 2042
63. C.S. Katsouras, S.A. Karabina, A.P. Tambaki Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms association with the severity of clinical presentation in patients with coronary heart disease J Cardiovasc Risk 8 5 2001 311 317
64. C. Gazzaruso, A. Garzaniti, P. Buscaglia Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus relationships to microvascular and neurological complications Acta Diabetol 35 1 1998 13 18
65. F. Kronenberg, M.F. Kronenberg, S. Kiechl Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis prospective results from the Bruneck study Circulation 100 11 1999 1154 1160
66. C. Gazzaruso, A. Garzaniti, S. Giordanetti Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients a role for lipoprotein(a) and apolipoprotein(a) polymorphism Diabetes Care 25 8 2002 1418 1424
67. T. Budde, C. Fechtrup, E. Bosenberg Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis Arterioscler Thromb 14 11 1994 1730 1736
68. K. Miwa, K. Nakagawa, N. Yoshida Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm J Am Coll Cardiol 35 5 2000 1200 1205
69. P. Stubbs, M. Seed, D. Lane Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes Eur Heart J 19 9 1998 1355 1364
70. U. Lundstam, J. Herlitz, T. Karlsson Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease J Intern Med 251 2 2002 111 118
71. H. Ohashi, H. Oda, M. Ohno Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients Kidney Int Suppl 71 1999 S242 S244
72. C.A. Glader, L.S. Birgander, H. Stenlund Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden J Intern Med 252 1 2002 27 35
73. G. Hoefler, F. Harnoncourt, E. Paschke Lipoprotein Lp(a). A risk factor for myocardial infarction Arteriosclerosis 8 4 1988 398 401
74. P.N. Durrington, M. Ishola, L. Hunt Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease Lancet 1 8594 1988 1070 1073
75. D.E. Wilcken, X.L. Wang, J. Greenwood Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents J Pediatr 123 4 1993 519 526
76. J.C. Vella, E. Jover Relation of lipoprotein(a) in 11- to 19-year-old adolescents to parental cardiovascular heart disease Clin Chem 39 3 1993 477 480
77. R.A. Hegele, P. Connelly, G. Cullen-Dean Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia Am J Cardiol 72 5 1993 402 406
78. E. Peros, D. Geroldi, A. D'Angelo Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease Int J Mol Med 13 2 2004 243 247
79. G.M. Kostner, A. Czinner, K.H. Pfeiffer Lipoprotein(a) concentrations as risk indicators for atherosclerosis Arch Dis Child 66 9 1991 1054 1056
80. D.E. Wilcken, X.L. Wang, N.P. Dudman The relationship between infant and parent Lp(a) levels Chem Phys Lipids 67-68 1994 299 304
81. S.R. Srinivasan, G.H. Dahlen, R.A. Jarpa Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study Circulation 84 1 1991 160 167
82. S. Pay, N. Ozcan, S.L. Tokgozoglu Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels Int J Cardiol 60 3 1997 301 305
83. B. Torbus-Lisiecka, H. Bukowska, M. Jastrzebska Lp(a), homocysteine and a family history of early ischemic cerebral stroke Nutr Metab Cardiovasc Dis 11 suppl 5 2001 52 59
84. K. Orth-Gomer, M.A. Mittleman, K. Schenck-Gustafsson Lipoprotein(a) as a determinant of coronary heart disease in young women Circulation 95 2 1997 329 334
85. M.A. Austin, C. Sandholzer, J.V. Selby Lipoprotein(a) in women twins heritability and relationship to apolipoprotein(a) phenotypes Am J Hum Genet 51 4 1992 829 840
86. G. Lindahl, E. Gersdorf, H.J. Menzel The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6 Hum Genet 81 2 1989 149 152
87. N. Rifai, G. Heiss, K. Doetsch Lipoprotein(a) at birth, in blacks and whites Atherosclerosis 92 2-3 1992 123 129
88. C. Gazzaruso, A. Garzaniti, P. Buscaglia Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age J Am Coll Cardiol 33 1 1999 157 163
89. T. Kazumi, T. Maeda, T. Masuda Concurrent development of hemiplegia and angina pectoris in a 46-year-old man with familial hypercholesterolemia and elevated serum Lp(a) concentrations J Atheroscler Thromb 1 2 1994 129 131
90. H.S. Isser, V.K. Puri, V.S. Narain Lipoprotein(a) and lipid levels in young patients with myocardial infarction and their first-degree relatives Indian Heart J 53 4 2001 463 466
91. M. Sandkamp, G. Assman Lipoprotein(a) in PROCAM participants and young myocardial infarction survivors A. Scanu Lipoprotein(a) 1990 Academic Press San Diego, CA 205 209
92. G.H. Dahlen Incidence of Lp(a) lipoproteins among populations A.M. Scanu Lipoprotein(a) 1990 Academic Press San Diego, CA 151 173
93. M. Parlavecchia, A. Pancaldi, R. Taramelli Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age Am J Cardiol 74 4 1994 346 351
94. G.H. Dahlen, K. Berg, T. Gillnas Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease Clin Genet 7 4 1975 334 341
95. J. Danesh, R. Collins, R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 10 2000 1082 1085
96. J.M. Pepin, J.A. O'Neil, H.F. Hoff Quantification of apo[a] and apoB in human atherosclerotic lesions J Lipid Res 32 2 1991 317 327
97. J. Kreuzer, M.B. Lloyd, D. Bok Lipoprotein(a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall Chem Phys Lipids 67-68 1994 175 190
98. J.A. Hearn, S.J. DeMaio Jr, G.S. Roubin Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease Am J Cardiol 66 17 1990 1176 1180
99. H. Yamamoto, M. Imazu, T. Yamabe Risk factors for restenosis after percutaneous transluminal coronary angioplasty role of lipoprotein(a) Am Heart J 130 6 1995 1168 1173
100. M. Miyata, S. Biro, S. Arima High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease Am Heart J 132 2 Pt. 1 1996 269 273
101. R.L. Desmarais, I.J. Sarembock, C.R. Ayers Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty Circulation 91 5 1995 1403 1409
102. L. Chiarugi, D. Prisco, E. Antonucci Lipoprotein(a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty Atherosclerosis 154 1 2001 129 135
103. P.K. Shah, J. Amin Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty Circulation 85 4 1992 1279 1285
104. C. Kim, G.T. Gau, T.G. Allison Relation of high lipoprotein(a) to other traditional atherosclerotic risk factors in patients with coronary heart disease Am J Cardiol 91 11 2003 1360 1363
105. Y. Igarashi, Y. Aizawa, T. Satoh Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty with special reference to the admission concentration of lipoprotein(a) Circ J 67 7 2003 605 611
106. M.N. Zairis, J.A. Ambrose, S.J. Manousakis The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting. The global evaluation of new events and restenosis after stent implantation study J Am Coll Cardiol 40 8 2002 1375
107. G.L. Cushing, J.W. Gaubatz, M.L. Nava Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation Arteriosclerosis 9 5 1989 593 603
108. M. Rath, A. Niendorf, T. Reblin Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients Arteriosclerosis 9 5 1989 579 592
109. H.F. Hoff, G. Beck, C. Skibinski Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients Circulation 77 6 1988 1238 1244
110. G.H. Daida, Y.J. Lee, H. Yokoi Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis Am J Cardiol 73 15 1994 1037 1040
111. H. Yamaguchi, Y.J. Lee, H. Daida Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA) LDL-apheresis angioplasty restenosis trial (L-ART) Chem Phys Lipids 67-68 1994 399 403
112. H. Adachi, A. Niwa, T. Shinoda Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis Artif Organs 19 12 1995 1243 1247
113. R. Christopher, K.M. Kailasanatha, D. Nagaraja Case-control study of serum lipoprotein(a) and apolipoproteins A-I and B in stroke in the young Acta Neurol Scand 94 2 1996 127 130
114. M. Nagayama, Y. Shinohara, T. Nagayama Lipoprotein(a) and ischemic cerebrovascular disease in young adults Stroke 25 1 1994 74 78
115. J. Woo, E. Lau, C.W. Lam Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese Stroke 22 2 1991 203 208
116. G. Zenker, P. Koltringer, G. Bone Lipoprotein(a) as a strong indicator for cerebrovascular disease Stroke 17 5 1986 942 945
117. G. Jurgens, P. Koltringer Lipoprotein(a) in ischemic cerebrovascular disease a new approach to the assessment of risk for stroke Neurology 37 3 1987 513 515
118. P.J. Schreiner, L.E. Chambless, S.A. Brown Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study. Atherosclerosis Risk in Communities Ann Epidemiol 4 5 1994 351 359
119. A. Murai, T. Miyahara, N. Fujimoto Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction Atherosclerosis 59 2 1986 199 204
120. S. Shintani, S. Kikuchi, H. Hamaguchi High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction Stroke 24 7 1993 965 969
121. L. Sun, Z. Li, H. Zhang Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese a multicenter case-control study in China Stroke 34 7 2003 1617 1622
122. U. Nowak-Gottl, R. Strater, A. Heinecke Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood Blood 94 11 1999 3678 3682
123. R. Strater, S. Becker, A. von Eckardstein Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study Lancet 360 9345 2002 1540 1545
124. A.G. Bostom, D.R. Gagnon, L.A. Cupples A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women The Framingham Heart Study Circulation 90 4 1994 1688 1695
125. R.J. Valentine, H.S. Kaplan, R. Green Lipoprotein(a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis a prospective, controlled analysis J Vasc Surg 23 1 1996 53 61 discussion 61-3
126. R.J. Valentine, P.A. Grayburn, G.L. Vega Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men Arch Intern Med 154 7 1994 801 806
127. G. Lippi, G.F. Veraldi, V. Dorucci Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery Scand J Clin Lab Invest 58 6 1998 497 504
128. B. Cantin, S. Moorjani, G.R. Dagenais Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study) Am J Cardiol 75 17 1995 1224 1228
129. C.H. Tseng Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan Diabetes Care 27 2 2004 517 521
130. M.D. Widmann, B.E. Sumpio Lipoprotein(a) a risk factor for peripheral vascular disease Ann Vasc Surg 7 5 1993 446 451
131. M.L. Koschinsky, S.M. Marcovina The relationship between lipoprotein(a) and the complications of diabetes mellitus Acta Diabetol 40 2 2003 65 76
132. A. Mohan, V. Srinivasan, R. Deepa Lipoprotein(a) role in diabetes and its vascular complications J Assoc Physicians India 49 2001 1100 1105
133. Y. Igarashi, M. Yamaura, M. Ito Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation a transesophageal echocardiographic study Am Heart J 136 6 1998 965 971
134. A. Csaszar, I. Karadi, E. Juhasz High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism Eur J Clin Invest 25 5 1995 368 370
135. R. Marcucci, A.A. Liotta, A.P. Cellai Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism Am J Med 115 8 2003 601 605
136. P.J. Levy, F. Gonzalez, D. Sheridan Diffuse arterial thrombosis in a young man with elevated lipoprotein(a) and minimal atherosclerosis Cardiovasc Surg 3 1 1995 56 59
137. E. Papagrigorakis, D. Iliopoulos, P.J. Asimacopoulos Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm Clin Genet 52 5 1997 262 271
138. B.F. Stewart, D. Siscovick, B.K. Lind Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study J Am Coll Cardiol 29 3 1997 630 634
139. T. Gotoh, T. Kuroda, M. Yamasawa Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study) Am J Cardiol 76 12 1995 928 932
140. H. Kapelrud, H.J. Bangstad, K. Dahl-Jorgensen Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria BMJ 303 6804 1991 675 678
141. F. Kronenberg, A. Lingenhel, K. Lhotta The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome Kidney Int 65 2 2004 606 612
142. F. Kronenberg, P. Konig, U. Neyer Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis J Am Soc Nephrol 6 1 1995 110 120
143. J.C. Longenecker, J. Coresh, S.M. Marcovina Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population the choices for healthy outcomes in caring for ESRD (CHOICE) study Am J Kidney Dis 42 1 2003 108 116
144. B.C. Astor, J.A. Eustace, M.J. Klag Race-specific association of lipoprotein(a) with vascular access interventions in hemodialysis patients the CHOICE Study Kidney Int 61 3 2002 1115 1123
145. M. Koch, B. Kutkuhn, E. Trenkwalder Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients J Am Soc Nephrol 8 12 1997 1889 1898
146. A.T. Webb, D.A. Reaveley, M. O'Donnell Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy Nephrol Dial Transplant 10 3 1995 354 357
147. M.D. Cressman, D. Abood, J. O'Neil Lp(a) and premature mortality during chronic hemodialysis treatment Chem Phys Lipids 67-68 1994 419 427
148. M. Seed, F. Hoppichler, D. Reaveley Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia N Engl J Med 322 21 1990 1494 1499
149. V.W. Armstrong, P. Cremer, E. Eberle The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels Atherosclerosis 62 3 1986 249 257
150. V.M.G. Maher, B.G. Brown, S.M. Marcovina Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA 274 22 1995 1771 1774
151. E.J. Schaefer, S. Lamon-Fava, J.L. Jenner Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial JAMA 271 13 1994 999 1003
152. B. Cantin, F. Gagnon, S. Moorjani Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study J Am Coll Cardiol 31 3 1998 519 525
153. C. Cobbaert, J.W. Jukema, A.H. Zwinderman Regression Growth Evaluation Statin Study (REGRESS) Study Group Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol J Am Coll Cardiol 30 6 1997 1491 1499
154. S.A. Grover, L. Coupal, X.P. Hu Identifying adults at increased risk of coronary disease How well do the current cholesterol guidelines work? JAMA 274 10 1995 801 806
155. M.J. Stampfer, F.M. Sacks, S. Salvini A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 6 1991 373 381
156. B.C. Solymoss, M. Marcil, E. Wesolowska Relation of coronary artery disease in women 60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio Am J Cardiol 72 17 1993 1215 1219
157. D.L. Rainwater, M.J. Ludwig, S.M. Haffner Lipid and lipoprotein factors associated with variation in Lp(a) density Arterioscler Thromb Vasc Biol 15 3 1995 313 319
158. N. Nago, K. Kayaba, J. Hiraoka Lipoprotein(a) levels in the Japanese population influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study Am J Epidemiol 141 9 1995 815 821
159. L.A. Sechi, F. Kronenberg, S. De Carli Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension JAMA 277 21 1997 1689 1695
160. C. Gazzaruso, A. Garzaniti, C. Falcone Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects Diabet Med 18 7 2001 589 594
161. J. Ruiz, J. Thillet, T. Huby Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes Diabetologia 37 6 1994 585 591
162. S. Agewall, B. Fagerberg Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men Clin Cardiol 25 6 2002 287 290
163. P.C. Harpel, X. Zhang, W. Borth Homocysteine and hemostasis pathogenic mechanisms predisposing to thrombosis J Nutr 126 suppl 4 1996 1285S 1289S
164. J.M. Foody, J.A. Milberg, K. Robinson Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women Arterioscler Thromb Vasc Biol 20 2 2000 493 499
165. P.C. Harpel, V.T. Chang, W. Borth Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism Proc Natl Acad Sci USA 89 21 1992 10193 10197
166. B. Cantin, J.P. Despres, B. Lamarche Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study) Am J Cardiol 89 6 2002 662 666
167. L.U. Gerdes, C. Gerdes, K. Kervinen The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction a substudy of the Scandinavian simvastatin survival study Circulation 101 12 2000 1366 1371
168. C. Gazzaruso, P. Buscaglia, A. Garzaniti Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension J Hypertens 15 3 1997 227 235
169. P.N. Hopkins, S.C. Hunt, P.J. Schreiner Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease results from the NHLBI Family Heart Study Atherosclerosis 141 2 1998 333 345
170. B.V. Howard, N.A. Le, J.D. Belcher Concentrations of Lp(a) in black and white young adults relations to risk factors for cardiovascular disease Ann Epidemiol 4 5 1994 341 350
171. W. Wang, D. Hu, E.T. Lee Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study Ann Epidemiol 12 2 2002 107 114
172. E.A. Enas, A. Senthilkumar, V. Chacko, N. Puthumana Dyslipidemia among Indo-Asians strategies for identification and management Brit J Diabetes Vasc Dis 5 2005 81 90
173. K. Hughes, T.C. Aw, P. Kuperan Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore J Epidemiol Community Health 51 4 1997 394 399
174. P.S. Low, C.K. Heng, N. Saha Racial variation of cord plasma lipoprotein(a) levels in relation to coronary risk level a study in three ethnic groups in Singapore Pediatr Res 40 5 1996 718 722
175. C. Sandholzer, D.M. Hallman, N. Saha Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups Hum Genet 86 6 1991 607 614
176. H.J. Parra, D. Arveiler, A.E. Evans A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study Arterioscler Thromb 12 6 1992 701 707
177. S.M. Haffner, K.K. Gruber, P.A. Morales Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites The San Antonio Heart Study Am J Epidemiol 136 9 1992 1060 1068
178. D. Bhatnagar, I.S. Anand, P.N. Durrington Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India Lancet 345 8947 1995 405 409
179. Y. Sakai, Y. Tomobuchi, Y. Toyoda A premenopausal woman presenting with acute myocardial infarction of three different coronary vessels within 1 year role of lipoprotein(a) Jpn Circ J 62 11 1998 849 853
180. C. Labeur, D. De Bacquer, G. De Backer Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography Clin Chem 38 11 1992 2261 2266
181. S. Sunayama, H. Daida, H. Mokuno Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age Circulation 94 6 1996 1263 1268
182. M.G. Shlipak, J.A. Simon, E. Vittinghoff Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause JAMA 283 14 2000 1845 1852
183. J.L. Jenner, J.M. Ordovas, S. Lamon-Fava Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study Circulation 87 4 1993 1135 1141
184. B. Salobir, M. Sabovic, P. Peternel Fibrinolytic parameters and lipoprotein(a) in young women with myocardial infarction Angiology 53 2 2002 157 163
185. H.W. Hahmann, D. Schatzer-Klotz, T. Bunte The significance of high levels of lipoprotein(a) compared with established risk factors in premature coronary artery disease differences between men and women Atherosclerosis 144 1 1999 221 228
186. L. Palaniappan, M.N. Anthony, C. Mahesh Cardiovascular risk factors in ethnic minority women aged less-than-or-equal 30 years Am J Cardiol 89 5 2002 524 529
187. P. Jha, E. Enas, S. Yusuf Coronary artery disease in Asian Indians prevalence and risk factors Asian Am Pac Isl J Health 1 2 1993 163 175
188. E.A. Enas, A. Senthilkumar, V. Juturu Coronary artery disease in women Indian Heart J 53 3 2001 282 292
189. D. Ogunyemi, F. Cuellar, W. Ku Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy Am J Perinatol 20 1 2003 17 24
190. K. Berg, B. Roald, H. Sande High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation Clin Genet 46 1994 52 56 (1 Spec. No.)
191. M.G. van Pampus, M.M. Koopman, H. Wolf Lipoprotein(a) concentrations in women with a history of severe preeclampsia - a case control study Thromb Haemost 82 1 1999 10 13
192. D. Crook, R. Howell, M. Sidhu Elevated serum lipoprotein(a) levels in young women with endometriosis Metabolism 46 7 1997 735 739
193. T. Atsumi, M.A. Khamashta, C. Andujar Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome J Rheumatol 25 1 1998 69 73
194. M. Yamazaki, H. Asakura, H. Jokaji Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome Thromb Haemost 71 4 1994 424 427
195. M. Szczepanski, A. Bauer, A. Gardas Antiphospholipid antibodies and lipoprotein(a) in women with recurrent fetal loss Int J Gynaecol Obstet 61 1 1998 39 44
196. H. Husby, B. Roald, R. Schjetlein High levels of Lp(a) lipoprotein in a family with cases of severe pre-eclampsia Clin Genet 50 1 1996 47 49
197. A.A. Ariyo, C. Thach, R. Tracy Lp(a) lipoprotein, vascular disease, and mortality in the elderly N Engl J Med 349 22 2003 2108 2115
198. G.G. Rhoads, G. Dahlen, K. Berg Lp(a) lipoprotein as a risk factor for myocardial infarction JAMA 256 18 1986 2540 2544
199. J.M. Foody, J.A. Milberg, G.L. Pearce Lipoprotein(a) associated with coronary artery disease in older women age and gender analysis Atherosclerosis 153 2 2000 445 451
200. K. Berg, O.C. Ro Lp(a) lipoprotein level and longevity Ann Genet 34 3-4 1991 264 269
201. E.A. Enas Coronary artery disease epidemic in Indians a cause for alarm and call for action J Indian Med Assoc 98 11 2000 694 695 697-702
202. E.A. Enas, S. Yusuf, J. Mehta Prevalence of coronary artery disease in Asian Indians Am J Cardiol 70 1992 945 949
203. A.L. Klatsky, M. Armstrong Cardiovascular risk factors among Asian Americans living in Northern California Am J Public Health 81 1991 1423 1428
204. L.O. Hughes, U. Raval, E. Raftery First myocardial infarctions in Asian and White men BMJ 298 1989 1345 1350
205. R. Balarajan Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales BMJ 302 6776 1991 560 564
206. C.Z. Chuang, P.N. Subramaniam, B.Y. LeGardeur Risk factors for coronary artery disease and levels of lipoprotein(a) and fat-soluble antioxidant vitamins in Asian Indians of USA Indian Heart J 50 3 1998 285 291
207. E.A. Enas Cardiovascular diseases in Asian Americans and Pacific Islanders Asian Am Pac Islander J Health 4 1996 119 120
208. E.A. Enas, A. Garg, M.A. Davidson Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America Indian Heart J 48 4 1996 343 353
209. S.H. Wild, S.P. Fortmann, S.M. Marcovina A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants Arterioscler Thromb Vasc Biol 17 2 1997 239 245
210. S.M. Grundy Primary prevention of coronary heart disease integrating risk assessment with intervention Circulation 100 9 1999 988 998
211. N. Forouhi, P. McKeigue How far can risk factors account for excess coronary mortality in South Asians? Can J Cardiol 13 suppl B 1997 47B
212. G.J. Miller, G.L. Beckles, G.H. Maude Ethnicity and other characteristics predictive of coronary heart disease in a developing community principal results of the St James Survey, Trinidad Int J Epidemiol 18 4 1989 808 817
213. S.K. Kamath, E.A. Hussain, D. Amin Cardiovascular disease risk factors in 2 distinct ethnic groups Indian and Pakistani compared with American premenopausal women Am J Clin Nutr 69 4 1999 621 631
214. H.R. Superko, E.A. Enas, P. Kotha Impaired cholesterol transport in Asian Indians J Am Coll Cardiol 37 2001 300A
215. C. Cobbaert, H. Kesteloot Serum lipoprotein(a) levels in racially different populations Am J Epidemiol 136 4 1992 441 449
216. H. Refsum, C.S. Yajnik, M. Gadkari Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians Am J Clin Nutr 74 2 2001 233 241
217. S. Anand, S. Yusuf, V. Vuksan Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet 356 9226 2000 279 284
218. A.J. Proudler, I.F. Godsland, R. Bruce Lipid and carbohydrate metabolic risk markers for coronary heart disease and blood pressure in healthy non-obese premenopausal women of different racial origins in the United Kingdom Metabolism 45 3 1996 328 333
219. V. Chopra, S. Vasisht, S. Gulati Serum levels of lipoprotein(a) and other lipids in angiographically defined coronary artery disease patients and healthy blood bank donors Indian J Med Sci 54 7 2000 284 289
220. R. Gupta, S. Kastia, S. Rastogi Lipoprotein(a) in coronary heart disease a case-control study Indian Heart J 52 4 2000 407 410
221. R. Gupta, S. Vasisht, V.K. Bahl Correlation of lipoprotein(a) to angiographically defined coronary artery disease in Indians Int J Cardiol 57 3 1996 265 270
222. M.V. Mammi, K. Pavithran, P. Abdu Rahiman Acute myocardial infarction in north Kerala - a 20 year hospital based study Indian Heart J 43 2 1991 93 96
223. C.G. Bahuleyan Hospital data on coronary heart disease from North Kerala G. Vijayaraghavan Cardiovascular Disease Prevention 1996 Trivandrum Medical College Trivandrum, India 54 59
224. E.A. Enas Why is there an epidemic of malignant CAD in young Indians? Asian J Clin Cardiol 1 1998 43 59
225. V. Muthusamy, V. Amuthan, V. Kumaravel Lipoprotein(a) and premature coronary artery disease Indian Heart J 52 2000 765
226. R. Deepa, A. Mohan, M. Rema Lipoprotein(a) in South Indian type 2 diabetic subjects in relation to diabetic vascular complications J Assoc Physicians India 50 5 2002 657 661
227. E.A. Enas Lipoprotein(a) is an important genetic risk factor for coronary artery disease in Asian Indians Am J Cardiol 88 2001 201 202
228. E.A. Enas, S.T. Jacob Emerging noninvasive biochemical measures potential explanation for ethnic differences in cardiovascular risk Arch Intern Med 159 1999 1812 1813
229. A. Misra Atherosclerosis in Indians and lipoprotein(a) J Assoc Physicians India 47 3 1999 313 317
230. E.A. Enas, A. Senthilkumar, H. Chennikkara Prudent diet and preventive nutrition from pediatrics to geriatrics current knowledge and practical recommendations Indian Heart J 55 4 2003 310 338
231. Z.W. Xiong, M.L. Wahlqvist, T.I. Ibiebele Relationship between plasma lipoprotein(a), apolipoprotein(a) phenotypes, and other coronary heart disease risk factors in a Melbourne South Asian population Clin Biochem 37 4 2004 305 311
232. K. Sundram, A. Ismail, K.C. Hayes Trans (elaidic) fatty acids adversely affect the lipoprotein profile relative to specific saturated fatty acids in humans J Nutr 127 3 1997 514S 520S
233. J.R. Guyton, G.H. Dahlen, W. Patsch Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B Arteriosclerosis 5 3 1985 265 272
234. S. Heyden, A. Von Eckardstein, H. Schulte Raised lipoprotein(a) in hypercholesterolaemic black students compared to age-matched whites in North and South Carolina Int J Epidemiol 23 2 1994 301 306
235. S.M. Marcovina, J.J. Albers, D.R. Jacobs Jr Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study Arterioscler Thromb 13 7 1993 1037 1045
236. P.J. Schreiner Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort the Atherosclerosis Risk in Communities (ARIC) Study Chem Phys Lipids 67-68 1994 405 410
237. A.R. Sharrett, C.M. Ballantyne, S.A. Coady Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 10 2001 1108 1113
238. D.J. Moliterno, E.V. Jokinen, A.R. Miserez No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans Arterioscler Thromb Vasc Biol 15 7 1995 850 855
239. NCEP III Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III National Institute of Health 2002 September2002. Report No. 02-5215.
240. S.A. Brown, R. Hutchinson, J. Morrisett Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb 13 8 1993 1139 1158
241. T.C. Wilcosky, P.O. Kwiterovich Jr, C.J. Glueck Dyslipoproteinemia in black participants. The Lipid Research Clinics Program Prevalence Study Circulation 73 1 Pt. 2 1986 I119 I125
242. F. Paultre, T.A. Pearson, H.F. Weil High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men Arterioscler Thromb Vasc Biol 20 12 2000 2619 2624
243. S.M. Marcovina, J.J. Albers, E. Wijsman Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans J Lipid Res 37 12 1996 2569 2585
244. F. Paultre, C.H. Tuck, B. Boden-Albala Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population Arterioscler Thromb Vasc Biol 22 1 2002 141 146
245. P.M. Ridker, C.H. Hennekens, M.J. Stampfer A prospective study of lipoprotein(a) and the risk of myocardial infarction JAMA 270 18 1993 2195 2199
246. M. Jauhiainen, P. Koskinen, C. Ehnholm Lipoprotein(a) and coronary heart disease risk a nested case-control study of the Helsinki Heart Study participants Atherosclerosis 89 1 1991 59 67
247. P.M. Ridker, M.J. Stampfer, C.H. Hennekens Plasma concentration of lipoprotein(a) and the risk of future stroke JAMA 273 16 1995 1269 1273
248. I.C. Klausen, A. Sjol, P.S. Hansen Apolipoprotein(a) isoforms and coronary heart disease in men a nested case-control study Atherosclerosis 132 1 1997 77 84
249. S.R. Holmer, C. Hengstenberg, H.G. Kraft Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction Circulation 107 5 2003 696 701
250. P. Cremer, D. Nagel, B. Labrot Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS) Eur J Clin Invest 24 7 1994 444 453
251. M.P. Coleman, T.J. Key, D.Y. Wang A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women Atherosclerosis 92 2-3 1992 177 185
252. G. Sigurdsson, A. Baldursdottir, H. Sigvaldason Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men Am J Cardiol 69 16 1992 1251 1254
253. N.J. Wald, M. Law, H.C. Watt Apolipoproteins and ischaemic heart disease implications for screening Lancet 343 8889 1994 75 79
254. M. Seed, K.L. Ayres, S.E. Humphries Lipoprotein(a) as a predictor of myocardial infarction in middle-aged men Am J Med 110 1 2001 22 27
255. A. Rosengren, L. Wilhelmsen, E. Eriksson Lipoprotein(a) and coronary heart disease a prospective case-control study in a general population sample of middle aged men BMJ 301 6763 1990 1248 1251
256. L. Simons, Y. Friedlander, J. Simons Lipoprotein(a) is not associated with coronary heart disease in the elderly cross-sectional data from the Dubbo study Atherosclerosis 99 1 1993 87 95
257. R.W. Evans, O. Shpilberg, B.J. Shaten Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial J Clin Epidemiol 54 1 2001 51 57
258. I.C. Klausen, U. Beisiegel, H.J. Menzel Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. The EARS Study. European Atherosclerosis Research Study Arterioscler Thromb Vasc Biol 15 8 1995 1001 1008
259. A.M. Scanu Lipoprotein(a) and the atherothrombotic process mechanistic insights and clinical implications Curr Atheroscler Rep 5 2 2003 106 113
260. S.M. Marcovina, Z.H. Zhang, V.P. Gaur Identification of 34 apolipoprotein(a) isoforms differential expression of apolipoprotein(a) alleles between American blacks and whites Biochem Biophys Res Commun 191 3 1993 1192 1196
261. S.A. Brown, J.D. Morrisett, E. Boerwinkle The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb 13 11 1993 1558 1566
262. H.G. Kraft, A. Lingenhel, S. Kochl Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease Arterioscler Thromb Vasc Biol 16 6 1996 713 719
263. M. Farrer, F.L. Game, C.J. Albers Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms Arterioscler Thromb 14 8 1994 1272 1283
264. L. Brazier, L. Tiret, G. Luc Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study Atherosclerosis 144 2 1999 323 333
265. F.S. Geethanjali, V.J. Jose, A.S. Kanagasabapathy Lipoprotein(a) phenotypes in south Indian patients with coronary artery disease Indian Heart J 54 1 2002 50 53
266. F.S. Geethanjali, K. Luthra, A. Lingenhel Analysis of the apo(a) size polymorphism in Asian Indian populations association with Lp(a) concentration and coronary heart disease Atherosclerosis 169 1 2003 121 130
267. J.K. Gambhir, D. Gambhir, J. Morreset Lipoprotein(a) in normal Indian subjects and and patients with coronary artery disease Indian Heart J 50 1998 563
268. H.G. Kraft, A. Lingenhel, R.W. Pang Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations the distribution of null alleles is non-random Eur J Hum Genet 4 2 1996 74 87
269. G. Alfthan, J. Pekkanen, M. Jauhiainen Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study Atherosclerosis 106 1 1994 9 19
270. W.Y. Craig, S.E. Poulin, N.R. Forster Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits Clin Chem 38 4 1992 550 553
271. B. Devanapalli, S. Lee, D. Mahajan Lipoprotein(a) in an immigrant Indian population sample in Australia Br J Biomed Sci 59 2 2002 119 122
272. F. Kronenberg, E. Trenkwalder, H. Dieplinger Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail Arterioscler Thromb Vasc Biol 16 12 1996 1568 1572
273. M. Matsubara, H. Akita, H. Shibuya Decreased longevity in Japanese men, associated with low-molecular-weight apolipoprotein(a) phenotypes Ann Clin Biochem 38 Pt. 2 2001 120 123
274. A. Serdar, D. Yesilbursa, Z. Serdar [Lipoprotein(a) as a risk factor for coronary artery disease in women and elderly patients] Anadolu Kardiyol Derg 1 4 2001 259 263 AXV-XVI
275. K.R. Kulkarni, D.W. Garber, M.K. Jones Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology J Lipid Res 36 11 1995 2291 2302
276. S.M. Marcovina, M.L. Koschinsky, J.J. Albers Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease recent advances and future directions Clin Chem 49 11 2003 1785 1796
277. S.M. Marcovina, J.J. Albers, B. Gabel Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a) Clin Chem 41 2 1995 246 255
278. P.M. Ridker, M.J. Stampfer, N. Rifai Novel risk factors for systemic atherosclerosis a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease JAMA 285 19 2001 2481 2485
279. F. Dati, J.R. Tate, S.M. Marcovina First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay - Lp(a) SRM 2B Clin Chem Lab Med 42 6 2004 670 676
280. S.M. Marcovina, J.J. Albers, A.M. Scanu Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a) Clin Chem 46 12 2000 1956 1967
281. E. Boerwinkle, C.C. Leffert, J. Lin Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations J Clin Invest 90 1 1992 52 60
282. V. Mooser, D. Scheer, S.M. Marcovina The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans Am J Hum Genet 61 2 1997 402 417
283. L. Hubinger, L.T. Mackinnon The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males Med Sci Sports Exerc 28 6 1996 757 764
284. L. Hubinger, L.T. Mackinnon, F. Lepre Lipoprotein(a) [Lp(a)] levels in middle-aged male runners and sedentary controls Med Sci Sports Exerc 27 4 1995 490 496
285. P. Fontana, V. Mooser, P. Bovet Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in black African males Arterioscler Thromb Vasc Biol 19 4 1999 1075 1082
286. E. Marth, G. Cazzolato, G. Bittolo Bon Serum concentrations of Lipoprotein(a) and other lipoprotein parameters in heavy alcohol consumers Ann Nutr Metab 26 1 1982 56 62
287. D.J. Jenkins, C.W. Kendall, A. Marchie Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial Circulation 106 11 2002 1327 1332
288. B.A. Clevidence, J.T. Judd, E.J. Schaefer Plasma lipoprotein(a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids Arterioscler Thromb Vasc Biol 17 9 1997 1657 1661
289. R.P. Mensink, P.L. Zock, M.B. Katan Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans J Lipid Res 33 10 1992 1493 1501
290. P.J. Nestel, M. Noakes, B. Belling Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet J Lipid Res 33 7 1992 1029 1036
291. S.M. Marcovina, H. Kennedy, G. Bittolo Bon Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania The Lugalawa Study Arterioscler Thromb Vasc Biol 19 5 1999 1250 1256
292. J. Eritsland, H. Arnesen, K. Berg Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation Scand J Clin Lab Invest 55 4 1995 295 300
293. H.J. Milionis, Z. Efstathiadou, A.D. Tselepis Lipoprotein(a) levels and apolipoprotein(a) isoform size in patients with subclinical hypothyroidism effect of treatment with levothyroxine Thyroid 13 4 2003 365 369
294. W.K. Min, J. Lee, J. Huh Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease Clin Chem 43 10 1997 1891 1895
295. S. Maeda, A. Abe, M. Seishima Transient changes of serum lipoprotein(a) as an acute phase protein Atherosclerosis 78 2-3 1989 145 150
296. P.M. Sweetnam, C.H. Bolton, L.G. Downs Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease the Caerphilly study Eur J Clin Invest 30 11 2000 947 956
297. D. Baldassarre, E. Tremoli, G. Franceschini Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients Stroke 27 6 1996 1044 1049
298. T.K. Mishra, S. Routray, U. Patnaik Lipoprotein(a) and lipid profile in young patients with angiographically proven coronary artery disease Indian Heart J 53 2001 585
299. G.H. Dahlen, H. Stenlund Lp(a) lipoprotein is a major risk factor for cardiovascular disease pathogenic mechanisms and clinical significance Clin Genet 52 5 1997 272 280
300. J.A. Hearn, B. Donohue, H. Ba'albaki Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty Am J Cardiol 69 8 1992 736 739
301. K.R. Kulkarni, D.W. Garber, S.M. Marcovina Quantification of cholesterol in all lipoprotein classes by the VAP-II method J Lipid Res 35 1 1994 159 168
302. A.M. Scanu, J. Hinman Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels Lipids 37 5 2002 439 444
303. J. Seman, C. DeLuca, J.L. Jenner Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study Clin Chem 45 7 1999 1039 1046
304. G.R. Thompson, V.M. Maher, S. Matthews Familial Hypercholesterolaemia Regression Study a randomised trial of low-density-lipoprotein apheresis Lancet 345 8953 1995 811 816
305. I.C. Klausen, L.U. Gerdes, H. Meinertz Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration Eur J Clin Invest 23 4 1993 240 245
306. S. van Wissen, T.J. Smilde, M.D. Trip Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia Heart 89 8 2003 893 896
307. E.J. Schaefer, J.R. McNamara, T. Tayler Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects Am J Cardiol 93 1 2004 31 39
308. K. Berg, G. Dahlen, B. Christophersen Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study Clin Genet 52 5 1997 254 261
309. J.C. LaRosa, J. He, S. Vupputuri Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials JAMA 282 24 1999 2340 2346
310. B. Pitt, D. Waters, W.V. Brown Atorvastatin versus Revascularization Treatment Investigators Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease N Engl J Med 341 2 1999 70 76
311. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 9326 2002 7 22
312. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 15 2004 1495 1504
313. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 13 2001 1711 1718
314. D.A. Shewmon, J.L. Stock, C.J. Rosen Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women Arterioscler Thromb 14 10 1994 1586 1593
315. L.A. Carlson, A. Hamsten, A. Asplund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J Intern Med 226 4 1989 271 276
316. M.H. Davidson Niacin a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events Curr Atheroscler Rep 5 5 2003 418 422
317. P.L. Canner, K.G. Berge, N.K. Wenger Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin J Am Coll Cardiol 8 6 1986 1245 1255
318. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 4 1975 360 381
319. J.M. Morgan, D.M. Capuzzi, J.R. Guyton Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia a placebo-controlled trial J Cardiovasc Pharmacol Ther 1 3 1996 195 202
320. J. McKenney New perspectives on the use of niacin in the treatment of lipid disorders Arch Intern Med 164 7 2004 697 705
321. R.H. Knopp, P. Alagona, M. Davidson Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Metabolism 47 9 1998 1097 1104
322. C.D. Meyers, M.C. Carr, S. Park Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia Ann Intern Med 139 12 2003 996 1002
323. M.L. Kashyap, M.E. McGovern, K. Berra Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia Am J Cardiol 89 6 2002 672 678
324. M.B. Elam, D.B. Hunninghake, K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial JAMA 284 10 2000 1263 1270
325. S.M. Grundy, G.L. Vega, M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial Arch Intern Med 162 14 2002 1568 1576
326. J. Pan, J.T. Van, E. Chan Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes Metabolism 51 9 2002 1120 1127
327. M.L. Wolfe, S.F. Vartanian, J.L. Ross Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia Am J Cardiol 87 4 2001 476 479
328. B.G. Brown, J.J. Albers, L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 19 1990 1289 1298
329. B.G. Brown, X.Q. Zhao, A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 22 2001 1583 1592
330. H.E. Bays, C.A. Dujovne, M.E. McGovern Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]) Am J Cardiol 91 6 2003 667 672
331. M. Akaike, H. Azuma, A. Kagawa Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases Clin Chem 48 9 2002 1454 1459
332. R. Straube, H. Kingreen Lipoprotein(a) immunapheresis in the treatment of familial lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease Ther Apher 2 3 1998 243 245
333. V.W. Armstrong, P. Schuff-Werner, T. Eisenhauer Heparin extracorporeal LDL precipitation (HELP) an effective apheresis procedure for lowering Lp(a) levels Chem Phys Lipids 67-68 1994 315 321
334. A.A. Kroon, W.R. Aengevaeren, T. van der Werf LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis Circulation 93 10 1996 1826 1835
335. K.J. Harjai Potential new cardiovascular risk factors left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen Ann Intern Med 131 5 1999 376 386
336. D.G. Hackam, S.S. Anand Emerging risk factors for atherosclerotic vascular disease a critical review of the evidence JAMA 290 7 2003 932 940